

NEW RESEARCH

Longitudinal Associations Between Physical Health Conditions in Childhood and Attention-Deficit/Hyperactivity Disorder Symptoms at Age 17 Years

Claire Reed, MSc , Samuele Cortese, MD, PhD , Henrik Larsson, PhD ,
Cédric Galéra, MD, PhD, Joanne Cotton, PhD , Valerie Brandt, PhD 

Objective: Although evidence suggests significant cross-sectional relationships between attention-deficit/hyperactivity disorder (ADHD) and several physical health conditions, less is known about their longitudinal associations. We investigated the cumulative effect of childhood physical health conditions on ADHD symptoms at age 17 years, controlling for environmental factors, ADHD medication status, and ADHD symptoms at age 3 years.

Method: Using Millennium Cohort Study data (weighted $n = 8,059$), we assessed whether 4 physical health clusters (sensory, neurological, atopic, and cardio-metabolic) were associated with scores on the ADHD subscale from the Strengths and Difficulties Questionnaire at age 17 years. Environmental factors were grouped into 5 cumulative risk indices: prenatal, perinatal, postnatal environment, postnatal maternal well-being, and socio-demographic factors. Regression analyses determined whether each physical health cluster was associated with ADHD score while controlling for environmental factors, ADHD medication, and earlier symptoms.

Results: Sensory, neurological, and cardio-metabolic clusters were all significantly associated with ADHD symptoms (β range = 0.04-0.09, $p < .001$). The overall model explained 2% of the variance. This rose to 21% ($\Delta R^2 = 0.06$) after adjusting for confounders. The sensory ($\beta = 0.06$) and neurological ($\beta = 0.06$) clusters remained significant ($R^2 = 0.21$, $\Delta R^2 = 0.06$), but the cardio-metabolic cluster was no longer a significant predictor.

Conclusion: Sensory or neurological conditions in childhood were associated with higher ADHD symptoms aged 17 after adjustment of confounders. This was not the case for atopic or cardio-metabolic conditions. These findings have implications for the care of children with sensory/neurological conditions and future research examining ADHD etiopathophysiology.

Key words: ADHD; physical health; environmental factors; ADHD medication

J Am Acad Child Adolesc Psychiatry 2023; ■(■):■-■. 

Attention-deficit/hyperactivity disorder (ADHD) is characterized by developmentally atypical, pervasive, and impairing symptoms of inattention and/or hyperactivity/impulsivity.¹ ADHD is a complex condition, with many comorbidities often complicating the diagnostic process, symptom management, and the quality of life of individuals with ADHD and their families.²

There is increasing evidence that ADHD is associated not only with mental health but also with physical conditions. A recent umbrella review³ encompassing 10 meta-analyses on ADHD found significant cross-sectional associations of ADHD with asthma and obesity when considering the most rigorous estimates (adjusted effect sizes). When considering unadjusted effect sizes, there was also

convincing or highly suggestive evidence for an association of ADHD with rhinitis and dermatitis.

Another recent birth cohort study⁴ ($n = 2,057$) assessed cross-sectional associations between ADHD symptoms and a large number of physical conditions at different time points during development, from age 5 months to 17 years. Some of the associations between ADHD symptoms and several physical conditions were consistently found in early childhood, middle childhood, and adolescence (eg, asthma, sleep problems), whereas others were present only at 1 time point, or were confounded by socioeconomic status or psychiatric comorbidities (eg, body mass index [BMI], dental caries). It is possible that either ADHD contributes to the increased risk for physical conditions, or that, vice

versa, physical conditions increase the risk of ADHD, or that common underlying factors contribute to both.⁵

However, although the bulk of the studies on the links between ADHD and physical conditions have addressed cross-sectional associations, longitudinal associations shedding light on the direction of the relationship have been less explored and have focused on single physical conditions, for example, obesity/increased body mass index.⁶

To address these limitations, the present study used a large-scale population-representative sample to examine the hypothesis that a cumulative number of physical health conditions across child development are associated with ADHD symptoms in adolescence.

When assessing this relationship, it is important to control for 2 important confounders. The first is environmental factors associated with an increased risk of ADHD. In this regard, there is meta-analytic evidence that ADHD is more common in children whose mothers smoked during pregnancy or experienced pre-eclampsia.⁷ Other risk factors include low birth weight and prematurity,⁸ and several indicators of socioeconomic disadvantage such as low family income, single-parent households, and low maternal education.⁹ The second important confounder is medications for ADHD that may have an impact on a number of physiologic systems; for instance, stimulants can negatively affect (at least at the beginning of the treatment) weight¹⁰ and sleep.¹¹

To gain insight into the longitudinal relationship between physical conditions and ADHD symptom development, we explored whether a cumulative number of physical disorders in childhood predicted ADHD symptoms at age 17 years, controlling for cumulative environmental risk, ADHD medication use, and ADHD symptoms reported at age 3 years.

METHOD

Sample

We used data from the Millennium Cohort Study (MCS), a longitudinal study that collected information from more than 19,000 UK families with children born between 2000 and 2002. To date, 7 waves of data have been collected, at ages 9 months and 3, 5, 7, 11, 14, and 17 years, respectively. In this study, as in previous research,¹² only the first sibling of each family was included (4.9% excluded) to prevent confounding effects of family membership. Participants were also excluded if data relating to their biological mother were unavailable (5.1%) or if all physical health predictor variables were missing (1.1%). As

in previous longitudinal analyses,¹³ only participants with non-missing outcome data at age 17 years were included in the analysis.

The number of participating families varied among waves, and households sampled from disadvantaged areas were more likely to withdraw.¹⁴ As such, standardized weights were applied to ensure the sample was representative of the UK population and to account for attrition rates. Weights were calculated by multiplying the wave 1 sample design weights by the non-response weights of each wave. As data in this study were taken from all waves, weights from the most recent data sweep were applied. Descriptive statistics for all weighted variables in the current sample for the study ($n = 8,059$) are reported in Tables 1 and 2. This study was approved by the University of Southampton Ethics Committee, in addition to the informed consent procedures obtained in the MCS.¹⁵ Parents gave written informed consent to the open use of the anonymized dataset.

Measures

Outcome Measure: Parent-Reported ADHD Symptoms. The parent-reported hyperactivity/inattention subscale of the Strengths and Difficulties Questionnaire (SDQ),¹⁶ measured at age 17 years, was used as a continuous dependent variable. The subscale hyperactivity/inattention is composed of 5 items (“restless, overactive, cannot stay still for long,” “constantly fidgeting or squirming,” “easily distracted, concentration wanders,” “thinks things out before acting,” “good attention span, sees tasks through to the end”). The SDQ items are rated from 0 to 2 points (0 = never, 1 = sometime true, 2 = certainly true or reverse coded for positive statements). Scores on the hyperactivity/inattention subscale range between 0 and 10, with a higher score indicating more ADHD symptoms. The SDQ has been found to be a valid measure with the hyperactivity/inattention subscale predicting ADHD diagnosis¹⁷ with a Cronbach alpha of 0.88, indicating good reliability. In the current sample, SDQ scores are significantly correlated ($p < .001$) across all 6 waves (ages 3-17 years) in which they are reported.

ADHD was diagnosed in a subset of children, with $n = 174$ children having an ADHD diagnosis by age 17 years. The main analysis was replicated with diagnosed ADHD as the outcome variable to test robustness of the results. We found that adolescents with an ADHD diagnosis at age 17 had a significantly higher hyperactivity/inattention SDQ score (mean = 5.09) than adolescents without an ADHD diagnosis (mean = 2.38; $t_{8386} = 16.31$, $p < .001$, $d = 1.25$).

TABLE 1 Weighted Frequencies of Sample Demographics and Other Environmental Risk Factors (N = 8,059)

	High-risk criteria	High risk	
		n	(%)
SES and demographics			
Sex ²⁴	Male	4,016	(49.8)
Ethnicity ²⁵	Any ethnicity other than white	968	(12)
Household income ²⁶	Below 60% median poverty indicator	2,502	(31.1)
Household crowding ¹²	Fewer rooms than people (excluding bathrooms)	743	(9.2)
Housing tenure ²⁷	Social housing or renting from local authority	1,825	(22.7)
Prenatal factors			
Maternal pre-pregnancy BMI ²⁸	>24.9	2,089	(25.9)
Antenatal blood pressure ⁷	Mother diagnosed with preeclampsia/hypertension	561	(7)
Maternal diabetes diagnosis ⁷	Mother has diabetes diagnosis	159	(2)
Smoking in pregnancy ^{29,30}	Mother smoked 1 or more cigarettes during pregnancy	1,716	(21.3)
Perinatal factors			
Birthweight ⁸	<2.5 kg	502	(6.2)
Gestation ^{8,31}	<37 weeks' gestation (premature)	663	(8.2)
Delivery ⁷	Cesarean delivery	1,584	(19.7)
Presentation/lie ⁷	Breech presentation/other abnormal lie	452	(5.6)
Postnatal environmental factors			
Maternal age ³²	≤19 y	671	(8.3)
Number of parents in household ²⁶	1 parent living in household	1,270	(15.8)
Mother's education ^{33,34}	Mother educated to <NVQ ^c level 3 (2 A-levels)	4,847	(60.1)
Breastfeeding ³⁵	No breastfeeding	2,480	(30.8)
Postnatal maternal well-being factors			
Maternal distress ^{36,37}	<4 on Rutter Malaise Inventory	358	(4.4)
Maternal mental health diagnosis ³⁸	Depression/anxiety diagnosis	2,008	(24.9)
Maternal attachment ^{39,40}	>22 on Condon Maternal Attachment Scale	1,870	(23.2)

Note: BMI = body mass index; NVQ = National Vocational Qualifications; SES = socioeconomic status.

Predictors: Physical Health Conditions. At each wave of data collection (age 9 months to 17 years), parents were asked about their child's physical health. This information was gathered in several ways, including asking whether they had ever seen a health care professional about any problems and, if yes, asking to give details. Parents were also asked about specific diagnoses (eg, "has [child's name] ever had asthma?"). Hospital admissions were also recorded along with the reason for admission, such as convulsions, fits, or epilepsy. We created variables to identify whether each child had ever experienced the condition. Physical conditions for which a diagnosis could be given repeatedly and on a temporary basis, such as infection or diarrhoea, were excluded.

We grouped the physical conditions into 4 clusters, according to similar physiological mechanisms, reflecting their grouping in the *International Classification of Diseases*,

Eleventh Revision (ICD-11), as well as existing empirical evidence¹⁸⁻²³: (1) sensory cluster (eyesight problems and hearing problems); (2) atopic cluster (eczema, asthma, and hay fever); (c) neurological cluster (fits and epilepsy, sleeping problems, stutter, movement problems, and other neurological disorders); and (4) cardio-metabolic cluster (obesity [at wave 7 only, to exclude the natural weight fluctuations of young children], diabetes, and any reported heart or circulation condition including congenital heart disease). Cohort members' cumulative physical risk was therefore indicated by the number of conditions that they had ever had in each cluster.

Control Variables: Cumulative Risk Indices and Age 3 Years SDQ score. Informed by previous evidence (Table 1²⁴⁻⁴⁰), a total of 20 environmental risk factors for ADHD were identified and controlled for within the

TABLE 2 Weighted Frequencies of Individual and Clustered Physical Health Conditions, and Cumulative Risk Indices (N = 8,059)

	n	(%)	No. of conditions, n (%)					
			0	1	2	3		
Sensory cluster			5,051 (62.7)	2,515 (31.2)	493 (6.1)			
Eyesight problems	1,802	(22.4)						
Hearing problems	1,700	(21.1)						
Atopic cluster			3,271 (40.6)	2,790 (34.6)	1,477 (18.3)	508 (6.3)		
Asthma	1,375	(17.1)						
Eczema	3,411	(42.3)						
Hay fever	2,482	(30.8)						
Neurological cluster			6,851 (85)	1,093 (13.6)	109 (1.4)	6 (0.1)		
Movement problems	452	(5.6)						
Neurological disorders	41	(0.5)						
Sleeping problems	82	(1)						
Stutter	261	(3.2)						
Fits or Epilepsy	491	(6.1)						
Cardio-metabolic cluster			5,983 (74.2)	2,052 (25.5)	24 (0.3)			
Diabetes	22	(0.3)						
Obesity age 17 y	2,031	(25.2)						
Cardiovascular disorders	47	(0.6)						
			No. of environmental risk factors, n (%)					
Cumulative Risk Indices			0	1	2	3	4	5
Prenatal factors			4,336 (53.8)	2,983 (37)	682 (8.5)	53 (0.7)	5 (0.1)	
Perinatal factors			5,747 (71.3)	1,596 (19.8)	556 (6.9)	148 (1.8)	13 (0.2)	
Postnatal environmental factors			2,707 (33.6)	2,535 (31.5)	1,917 (23.8)	701 (8.7)	199 (2.5)	
Postnatal maternal well-being factors			4,625 (57.4)	2,719 (33.7)	622 (7.7)	90 (1.1)		
Socioeconomic status and demographics			2,229 (27.7)	3,175 (39.4)	1,431 (17.8)	901 (11.2)	298 (3.7)	24 (0.3)

available MCS data.⁴¹ Data were collected during interviews with parents at the first data sweep (age 9 months). Individual risk factors were classified as either “high risk” or “low risk” (eg, cesarean delivery yes/ no). Continuous variables were assigned a cut-off with reference to previous literature (Table 1). Risk factors were grouped and totaled to create 5 cumulative risk indices (CRIs) as follows: (1) prenatal risk index, including maternal pre-pregnancy BMI, blood pressure problems in pregnancy, maternal diabetes, and smoking during pregnancy; (2) perinatal risk index, including birth weight, gestation, delivery method, and pregnancy lie/presentation; (3) postnatal risk (environment) index, including maternal age, number of parents in the household, maternal education, and breastfeeding; (4) postnatal risk (maternal well-being) index, including maternal distress, maternal depression/anxiety, and maternal attachment. Maternal distress was assessed using a 9-item short form version⁴² of the Rutter Malaise Inventory.⁴³ The highest loading items in the first principal factor were used to

create the 9-item scale measuring psychological distress. Mothers were asked a series of questions requiring a yes/no response such as “Do you often feel miserable or depressed?” High-risk maternal distress was indicated by a score of ≥ 4 ,³⁷ and psychometric properties are reported to be good.⁴⁴ A diagnosis of depression and/or anxiety was also included in the maternal well-being index, along with maternal attachment measured, using a 6-item modified version of the Condon Maternal Attachment Questionnaire.⁴⁵ In this scale, mothers are asked about their feelings in different situations, such as when they are caring for or having to leave their infant. Responses were recoded to ensure that all items followed the same scale of 1 to 5, which was then summed to give a total score out of 30. In line with previous literature,⁴⁰ high risk was categorized as the 25% of scores with the lowest attachment. (5) The fifth CRI comprised socioeconomic status and demographic risk index, including sex, ethnicity, household income, housing tenure, and overcrowding.

To account for ADHD symptoms experienced at a younger age, the SDQ score reported by parents at age 3 years was added as an additional predictor.

ADHD Medication. Only at wave 6, when cohort members were 14 years of age, parents were asked if their child was taking any prescribed medication for ADHD. A list of possible medications was given, including both stimulants and non-stimulants, and the variable was coded as yes if parents indicated their child was taking any medication on the list.

Statistical Analysis. Stepwise multiple regression analysis was conducted using IBM SPSS Statistics for Windows (version 28.0) to analyze the relationship between the physical health clusters and ADHD symptoms at age 17 years before and after controlling for cumulative environmental risk, ADHD medication, and age 3 SDQ score. SDQ scores on the hyperactivity/inattention subscale at age 17 years were entered as the dependent variable in all 4 regression models. The predictors entered into each model were as follows: model 1, physical health clusters; model 2, physical health clusters and cumulative risk indices; model 3, physical health clusters, cumulative risk indices, and ADHD medication; and model 4, physical health clusters, cumulative risk indices, ADHD medication, and SDQ score at age 3 years. Variance inflation factor values did not indicate multicollinearity for any of the variables. To ensure correct temporal ordering of the regression model, physical health diagnoses from all timepoints were used to predict ADHD symptoms and diagnosis at age 17 years. However, to confirm robustness of the findings when accounting for earlier ADHD symptoms, we included in the main analysis a fourth regression model with an SDQ score at age 3 years as an additional predictor. To show further robustness of the results, model 3 was repeated as a binary logistic regression with ADHD diagnosis (yes/no) as the outcome.

RESULTS

Weighted frequencies of physical health clusters and cumulative risk indices are reported in Table 2. As clusters were formed based on physiological similarity, they consisted of differing numbers of conditions and proportional frequencies. For example, the cardio-metabolic cluster consisted of 3 conditions with obesity markedly more prevalent than the other 2 disorders, whereas the sensory cluster consisted of 2 conditions with similar frequencies. In total, 91 children (1%) were taking ADHD medication, and the average SDQ score at age 17 was 2.64 (SD = 2.34).

Skewness and kurtosis were found to be within the normal range.

Model 1 (physical health clusters only) was overall significant ($F_{4,5411} = 29.37, p < .001$) and explained 2% of the variance. As individual predictors, the sensory ($\beta = 0.08, p < .001$), neurological ($\beta = 0.10, p < .001$), and cardio-metabolic ($\beta = 0.04, p < .001$) clusters all significantly predicted ADHD symptoms at age 17 years. Model 2 (physical health clusters + CRIs) was also statistically significant ($F_{9,5406} = 61.59, p < .001$), with 10% of the variance explained ($R^2_{\text{adj}} = 0.09, \Delta R^2 = 0.07$). Again, the sensory ($\beta = 0.08, p < .001$) and neurological ($\beta = 0.09, p < .001$) clusters were significantly associated with ADHD symptoms, but the cardio-metabolic cluster was no longer a significant predictor. This remained unchanged in model 3 ($F_{10,5405} = 96.37, p < .001$), with only the sensory ($\beta = 0.07, p < .001$) and neurological ($\beta = 0.09, p < .001$) clusters significantly predicting ADHD symptoms at age 17 years. Overall, model 3 explained 15% of the variance ($R^2_{\text{adj}} = 0.15, \Delta R^2 = 0.06$). Model 4 was again overall significant ($F_{11,5404} = 129.27, p < .001$). The model explained 21% of the variance ($R^2_{\text{adj}} = 0.21, \Delta R^2 = 0.06$) with the sensory ($\beta = 0.06, p < .001$) and neurological cluster ($\beta = 0.06, p < .001$) significantly predicting age ADHD symptoms at age 17 years. The atopic cluster was not a significant predictor in any of the 4 regression models. The CRIs all significantly predicted ADHD symptoms in both model 2 and model 3 (β range = 0.03-0.18). In model 4, all CRIs significantly predicted ADHD symptoms except perinatal factors. A summary of the regression statistics can be found in Table 3. The mean SDQ scores for each cumulative number of conditions in each cluster are shown in Figure 1.

A binary logistic regression with ADHD diagnosis as the outcome variable showed that the sensory cluster significantly predicted ADHD diagnosis ($b = 0.27, p = .020, OR = 1.31; 95\% CI = 1.04, 1.65$).

The neurological cluster also significantly predicted ADHD diagnosis ($b = 0.66, p < .001, OR = 1.94; 95\% CI = 1.48, 2.53$). Each additional neurological condition almost doubled the odds of an ADHD diagnosis.

DISCUSSION

This is the first study to analyze the longitudinal association between a broad range of physical conditions in childhood and ADHD symptoms at age 17 years, controlling for cumulative environmental risk factors for ADHD, ADHD medication status, and earlier ADHD symptoms. The sensory and neurological clusters were both significant

TABLE 3 Regression Statistics for All Models With Strengths and Difficulties Questionnaire (SDQ) Score at Age 17 Years as the Outcome Variable

	R²	R² change	B	β	95% CI	
					LL	UL
Model 1	0.02	0.02				
Constant			2.10**		2.00	2.20
Clusters						
Sensory			0.31**	0.09	0.22	0.41
Neurological			0.50**	0.09	0.36	0.64
Atopic			0.05	0.02	−0.02	0.11
Cardio-metabolic			0.17**	0.04	0.04	0.31
Model 2	0.09	0.07				
Constant			1.27**		1.15	1.39
Clusters						
Sensory			0.28**	0.08	0.19	0.37
Neurological			0.44**	0.08	0.38	0.64
Atopic			0.04	0.02	−0.03	0.09
Cardio-metabolic			0.04	0.01	−0.08	0.16
CRIs						
Prenatal risk			0.22**	0.07	0.14	0.30
Perinatal risk			0.09*	0.03	0.01	0.16
Mother environment			0.26**	0.12	0.26	0.38
Mother wellbeing			0.18**	0.05	0.15	0.31
SES and demographics			0.40**	0.18	0.31	0.42
Model 3	0.15	0.06				
Constant			1.34**		1.23	1.46
Clusters						
Sensory			0.28**	0.08	0.17	0.34
Neurological			0.40**	0.08	0.35	0.60
Atopic			0.02	0.01	−0.05	0.07
Cardio-metabolic			0.05	0.01	−0.06	0.17
CRIs						
Prenatal risk			0.19**	0.06	0.11	0.27
Perinatal risk			0.08*	0.03	0.01	0.15
Mother environment			0.23**	0.10	0.24	0.36
Mother wellbeing			0.14**	0.04	0.11	0.27
SES and demographics			0.36**	0.16	0.27	0.38
ADHD medication			4.86**	0.24	4.35	5.27
Model 4	0.21	0.06				
Constant			0.70**		0.56	0.84
Clusters						
Sensory			0.22**	0.06	0.13	0.31
Neurological			0.32**	0.06	0.20	0.45
Atopic			0.01	0.00	−0.05	0.07
Cardio-metabolic			0.01	0.00	−0.11	0.13
CRIs						
Prenatal risk			0.16**	0.05	0.08	0.24
Perinatal risk			0.07	0.02	−0.01	0.14
Mother environment			0.16**	0.07	0.10	0.22
Mother well-being			0.08*	0.02	0.001	0.16
SES and demographics			0.27**	0.12	0.21	0.32

(continued)

TABLE 3 Continued

	R ²	R ² change	B	β	95% CI	
					LL	UL
ADHD medication			4.39**	0.22	3.91	4.87
SDQ score at age 3 y			0.25**	0.25	0.22	0.27

Note: ADHD = attention-deficit/hyperactivity disorder; CRIs = cumulative risk indices; LL = lower limit; SES = socioeconomic status; UL = upper limit. *p < .05; **p < .001.

predictors of hyperactivity/ inattention symptoms at age 17 years and remained so after controlling for confounders. Moreover, the odds of having an ADHD diagnosis at age 17 years was almost twice as likely when adolescents had pre-dating neurological issues. The atopic cluster was not a significant predictor in any of the regression models, and, after controlling for environmental risk and ADHD medication, the cardio-metabolic cluster was also not a significant predictor.


Children with more sensory conditions had higher hyperactivity and inattention symptoms at age 17 years. This is in line with previous studies showing that both eyesight and hearing problems increase the risk of ADHD.⁴⁶⁻⁴⁸ Our findings build on this known association between ADHD and eyesight and hearing problems by showing that the likelihood of hyperactivity and inattention symptoms increases as the number of sensory conditions increases. DeCarlo *et al.*⁴⁸ proposed that sensory disorders place a large demand on executive functioning. Sensory problems may deplete executive functioning skills, leading to a reduced ability to

successfully perform tasks known to be impaired in ADHD, such as those requiring organization and concentration. It follows, therefore, that an increased number of sensory conditions may exacerbate inattention or hyperactivity symptoms in people who may already struggle with executive functioning.

This raises the question as to which should be explored in future research, of whether hearing and eyesight problems magnify existing symptoms, mimic ADHD symptoms that may otherwise not be present, or whether ADHD and sensory problems may share neurobiological underpinnings.⁴⁹ Our findings suggest that, to maintain quality of life, people with sensory disorders may need support with symptoms beyond those primarily associated with their health condition, because people with high levels of ADHD symptoms often experience a poorer quality of life, even if they do not meet the criteria for a diagnosis of ADHD.⁵⁰

A higher number of neurological conditions during development also significantly predicted ADHD symptoms at age 17 years when controlling for risk factors, medication,

FIGURE 1 Weighted Mean Strengths and Difficulties Questionnaire (SDQ) Scores for Cumulative Numbers of Conditions in Each Physical Health Cluster



and earlier ADHD symptoms. This is in line with previous studies reporting associations between ADHD and individual neurological conditions, such as stutter⁵¹ and epilepsy.⁵² Sleep problems, stutter, and epilepsy are all known to individually predict ADHD, as well as each other.²¹ Our results expand this knowledge by showing that a cumulation of neurological conditions further increases the likelihood of experiencing ADHD symptoms and an ADHD diagnosis later on in adolescence.

Previous literature has suggested that this relationship may be bi-directional,⁵³ as ADHD and conditions such as epilepsy may have shared risk factors or a shared neurobiological origin, with each predicting an increased risk of the other. Previous studies have found a shared genetic association between ADHD and neurological conditions, such as epilepsy,⁵⁴ and sleep problems.⁵⁵ It is possible that some genetic variants affect several neurological as well as mental conditions increasing polygenic risk.⁵⁶

Neurological conditions such as epilepsy are also known to have an impact on executive functioning networks⁵⁷ that may modulate ADHD symptom expression. Executive functions involve the frontal cortex,⁵⁸ which is associated with both epilepsy and ADHD.⁵⁴ Alterations in executive functioning networks that are associated with ADHD and neurological conditions may offer another explanation of the comorbidity between the conditions.

Contrary to previous research,⁵⁹ atopic disorders were not significantly associated with higher ADHD symptoms. This result was surprising, considering the wealth of evidence to support an association between atopic conditions and ADHD. Both eczema and hay fever had frequencies higher than expected and notably higher than other conditions (42.3% and 30.8%, respectively). It may be that these conditions were over-reported in the sample, which influenced the results. Future research using clinical diagnoses rather than parent-reported physical conditions may reduce measurement error and shed light on the association between cumulative atopic conditions and ADHD symptoms. Another possible explanation for our findings is that individual conditions predict ADHD symptoms, but that an accumulation of conditions does not increase the likelihood further.

This may also be the case for cardio-metabolic disorders, as the cardio-metabolic cluster also produced different results from the sensory and neurological clusters. The cumulative effect of cardio-metabolic conditions significantly predicted ADHD symptoms in the first regression model but not when controlling for environmental risk or ADHD medication. Previous research has reported an increased likelihood of developing diabetes in young people with ADHD, even after controlling for medication and

demographic factors.⁶⁰ Our findings suggest that this relationship may not be bi-directional, as cardiometabolic conditions did not predict an increase in hyperactivity/inattention symptoms. Rather than an accumulation of cardiometabolic conditions being associated with an increase in hyperactivity/inattention symptoms, it may be that environmental factors, or even other ADHD-related features such as impulsive decision making, are driving this relationship. These findings add weight to the complexity of the association between physical health and ADHD, demonstrating the influence of environmental risk on this relationship. For cardio-metabolic conditions at least, an individual's environment may play a larger part in determining the nature of the relationship.

All cumulative risk indices were themselves significantly associated with ADHD symptoms at age 17 years. The postnatal mother environment and socioeconomic status/demographics indices had the largest effect size, and both consisted of environmental factors that are considered to reflect mainly psychosocial rather than biological influences compared to the other indices. For example, gestation and birth weight are irreversible factors that affect a child's biology at a fixed point in time, potentially with long-term consequences. Factors affecting the whole household, such as income or housing tenure, have a greater effect on a child's physical environment, but they are also subject to greater fluctuation, and their influence may vary, depending on changes over time. This suggests that further investigation is warranted to explore how different environmental factors affect the relationship between cumulative physical conditions and ADHD.

This study has several strengths. It used a large sample, weighted to represent the general population. Data were obtained longitudinally, allowing analysis of environmental risk before the age of 3 years as a predictor of ADHD symptoms in later adolescence. It is also the first study to control for both environmental risk and medication use while examining the cumulative effect of several physical health conditions. The results further our insight into the pathophysiology of ADHD, and point to associations that may eventually inform clinical practice in terms of implementation of additional support programs. A key area for future research would be to explore the effects of early treatment and support for physical conditions on later development of ADHD symptoms. However, when considering their possible clinical implications, our findings should be interpreted with caution. Although the SDQ differentiated well between children with and without an ADHD diagnosis, it is not a screening instrument for ADHD. The sensitivity analyses that we conducted with ADHD diagnosis are limited by only a subset of children

having been evaluated for ADHD; therefore, our figures are likely underestimated. However, the consistency of the results in our sensitivity analysis indicates that our findings may extend to cases with a categorical diagnosis. There are some additional limitations to consider. First, the analyses were restricted by the amount and variety of physical health and environmental data available. Second, this study looked at physical health only as a predictor of ADHD symptoms, and did not explore the reverse relationship or the possibility of a bi-directional association. Third, because of a lack of data, it was not possible to analyze the effect of parental history of ADHD or physical health. ADHD is known to be highly heritable,⁶¹ as are many physical health conditions. Therefore, it is likely that a parent's health and neurodiversity may have an impact on both ADHD symptoms and the physical health of their child, as well as the home environment.

In summary, this study found a significant relationship between a number of cumulative physical disorders diagnosed during childhood and ADHD symptoms in adolescence. The results indicated that sensory disorders and neurological disorders predicted ADHD symptoms even when relevant environmental risk was controlled for, suggesting possible biological commonalities, including genetic association.

Accepted June 26, 2023.

Mrs. Reed, Prof. Cortese, and Dr. Brandt are with the University of Southampton, Southampton, United Kingdom. Dr. Cortese is also with Solent NHS Trust, Southampton, United Kingdom; the University of Nottingham, Nottingham, United Kingdom; Hassenfeld Children's Hospital at NYU Langone, New York; and the University Child Study Center, New York. Prof. Larsson is with Karolinska Institute, Stockholm, Sweden, and Örebro University, Örebro,

Sweden. Prof. Galéra is with the University of Bordeaux, Bordeaux, France; INSERM, Bordeaux Population Health Center, UMR1219, Bordeaux, France; Centre Hospitalier Perrens, Bordeaux, France; Research Unit on Children's Psychosocial Maladjustment, Montreal, QC, Canada. Dr. Cotton is with the University of Cambridge, Cambridge, United Kingdom.

The authors have reported no funding for this work.

Author Contributions

Conceptualization: Reed, Cortese, Larsson, Galéra, Cotton, Brandt

Formal analysis: Reed, Brandt

Methodology: Reed, Cortese, Larsson

Supervision: Cortese, Brandt

Writing – original draft: Reed

Writing – review and editing: Reed, Cortese, Larsson, Galéra, Cotton, Brandt

The authors are grateful to the Centre for Longitudinal Studies (CLS), UCL Social Research Institute, for the use of these data and to the UK Data Service for making them available. However, neither CLS nor the UK Data Service bear any responsibility for the analysis or interpretation of these data.

Disclosure: Prof. Cortese has declared honoraria and reimbursement for travel and accommodation expenses for lectures from the following non-profit associations: Association for Child and Adolescent Central Health (ACAMH), Canadian ADHD Alliance Resource (CADDRA), British Association of Pharmacology (BAP), and from Healthcare Convention for educational activity on ADHD. Prof. Larsson has acknowledged financial support from the European Union's Horizon 2020 research and innovation programme under grant agreement number 965381, the Swedish Research Council (2018-02599; 2022-01119) and the Swedish Brain Foundation (FO2021-0115). Prof. Larsson has reported receiving grants from Shire Pharmaceuticals; personal fees from and serving as a speaker for Medice, Shire/Takeda Pharmaceuticals and Evolan Pharma AB; and sponsorship for a conference on attention-deficit/hyperactivity disorder from Shire/Takeda Pharmaceuticals and Evolan Pharma AB, all outside the submitted work. Prof. Larsson is editor-in-chief of *JCPP Advances*. Dr. Cotton was funded by an ESRC/UKRI postdoctoral fellowship, Grant number: G108309 (October 2020 - August 2022). Dr. Brandt has acknowledged financial support from the Academy of Medical Sciences. Prof. Galéra and Mrs. Reed have reported no biomedical financial interests or potential conflicts of interest.

Correspondence to Claire Reed, MSc, School of Psychology, University of Southampton, University Road, Southampton SO17 1BJ, United Kingdom; e-mail: c.l.reed@soton.ac.uk

0890-8567/\$36.00/©2023 American Academy of Child and Adolescent Psychiatry. Published by Elsevier Inc. This is an open access article under the CC BY license (<http://creativecommons.org/licenses/by/4.0/>).

<https://doi.org/10.1016/j.jaac.2023.06.016>

REFERENCES

- American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 5th ed (DSM-5). American Psychiatric Publishing. 2013. <https://doi.org/10.1176/appi.books.9780890425596>
- Reale L, Bartoli B, Cartabia M, *et al.* Comorbidity prevalence and treatment outcome in children and adolescents with ADHD. *Eur Child Adolesc Psychiatry*. 2017;26(12):1443-1457. <https://doi.org/10.1007/s00787-017-1005-z>
- Arrondo G, Solmi M, Dragioti E, *et al.* Associations between mental and physical conditions in children and adolescents: an umbrella review. *Neurosci Biobehav Rev*. 2022;104662. <https://doi.org/10.1016/j.neubiorev.2022.104662>
- Galéra C, Cortese S, Orri M, *et al.* Medical conditions and attention-deficit/hyperactivity disorder symptoms from early childhood to adolescence. *Mol Psychiatry*. 2021;1-9. <https://doi.org/10.1038/s41380-021-01357-x>
- Hané T, Cortese S. Attention deficit/hyperactivity-disorder and obesity: a review and model of current hypotheses explaining their comorbidity. *Neurosci Biobehav Rev*. 2018; 92:16-28. <https://doi.org/10.1016/j.neubiorev.2018.05.017>
- Kase BE, Rommelse N, Chen Q, *et al.* Longitudinal associations between symptoms of ADHD and BMI from late childhood to early adulthood. *Pediatrics*. 2021;147(6). <https://doi.org/10.1542/peds.2020-036657>
- Arango C, Dragioti E, Solmi M, *et al.* Risk and protective factors for mental disorders beyond genetics: an evidence-based atlas. *World Psychiatry*. 2021;20(3):417-436. <https://doi.org/10.1002/wps.20894>
- Serati M, Barkin JL, Orsenigo G, Altamura AC, Buoli M. Research review: the role of obstetric and neonatal complications in childhood attention deficit and hyperactivity disorder—a systematic review. *J Child Psychol Psychiatry*. 2017;58(12):1290-1300. <https://doi.org/10.1111/jcpp.12779>
- Russell AE, Ford T, Williams R, Russell G. The association between socioeconomic disadvantage and attention deficit/hyperactivity disorder (ADHD): a systematic review. *Child Psychiatry Hum Dev*. 2016;47(3):440-458. <https://doi.org/10.1007/s10578-015-0578-3>
- Carucci S, Balia C, Gagliano A, *et al.* Long term methylphenidate exposure and growth in children and adolescents with ADHD. A systematic review and meta-analysis. *Neurosci Biobehav Rev*. 2021;120:509-525. <https://doi.org/10.1016/j.neubiorev.2020.09.031>
- Faraone SV, Po MD, Komolova M, Cortese S. Sleep-associated adverse events during methylphenidate treatment of attention-deficit/hyperactivity disorder: a meta-analysis. *J Clin Psychiatry*. 2019;80(3):19675. <https://doi.org/10.4088/JCP.18r12210>
- Flouri E, Midouhas E, Ruddy A, Moulton V. The role of socio-economic disadvantage in the development of comorbid emotional and conduct problems in children with ADHD. *Eur Child Adolesc Psychiatry*. 2017;26(6):723-732. <https://doi.org/10.1007/s00787-017-0940-z>
- Brandt V, Hall C, Eisenbarth H, Hall J. Mutual relationships between head injury and conduct problems in children aged 9 months to 14 years in the UK Millennium Cohort Study. *medRxiv*. 2022. <https://doi.org/10.1101/2022.01.09.22268970>
- Ploubidis GB, Mostafa T. Millennium Cohort: Study Sixth Survey 2015-2016. Technical report on response (age 14). Centre for Longitudinal Studies, UCL Institute of Education; 2017.

15. Shepherd P, Gilbert E. British Cohort Study ethical review and consent. London: Centre for Longitudinal Studies; 2019.
16. Goodman R. The Strengths and Difficulties Questionnaire: a research note. *J Child Psychology Psychiatry*. 1997;38(5):581-586. <https://doi.org/10.1111/j.1469-7610.1997.tb01545.x>
17. Hall CL, Guo B, Valentine AZ, *et al.* The validity of the Strengths and Difficulties Questionnaire (SDQ) for children with ADHD symptoms. *PLoS One*. 2019;14(6):e0218518. <https://doi.org/10.1371/journal.pone.0218518>
18. World Health Organization. International Classification of Diseases—Eleventh Revision. World Health Organization; 2019.
19. Chen M-H, Su T-P, Chen Y-S, *et al.* Is atopy in early childhood a risk factor for ADHD and ASD? A longitudinal study. *J Psychosom Res*. 2014;77(4):316-321. <https://doi.org/10.1016/j.jpsychores.2014.06.006>
20. Eklund H, Findon J, Cadman T, *et al.* Needs of adolescents and young adults with neurodevelopmental disorders: comparisons of young people and parent perspectives. *J Autism Dev Disord*. 2018;48:83-91. <https://doi.org/10.1007/s10803-017-3295-x>
21. Merlo S, Briley PM. Sleep problems in children who stutter: evidence from population data. *J Commun Disord*. 2019;82:105935. <https://doi.org/10.1016/j.jcomdis.2019.105935>
22. Prueett DG, Shaw DM, Chen H-H, *et al.* Identifying developmental stuttering and associated comorbidities in electronic health records and creating a phenome risk classifier. *J Fluency Disord*. 2021;68:105847. <https://doi.org/10.1016/j.jfludis.2021.105847>
23. Garcia-Argibay M, du Rietz E, Lu Y, *et al.* The role of ADHD genetic risk in mid-to-late life somatic health conditions. *Transl Psychiatry*. 2022;12(1):152. <https://doi.org/10.1038/s41398-022-01919-9>
24. Pinares-Garcia P, Stratikopoulos M, Zagato A, Loke H, Lee J. Sex: a significant risk factor for neurodevelopmental and neurodegenerative disorders. *Brain Sci*. 2018;8(8):154. <https://doi.org/10.3390/brainsci8080154>
25. Assari S, Caldwell CH. Family income at birth and risk of attention deficit hyperactivity disorder at age 15: racial differences. *Children*. 2019;6(1):10. <https://doi.org/10.3390/children6010010>
26. Russell G, Ford T, Rosenberg R, Kelly S. The association of attention deficit hyperactivity disorder with socioeconomic disadvantage: alternative explanations and evidence. *J Child Psychol Psychiatry*. 2014;55(5):436-445. <https://doi.org/10.1111/jcpp.12170>
27. Russell AE, Ford T, Russell G. Socioeconomic associations with ADHD: findings from a mediation analysis. *PLoS One*. 2015;10(6):e0128248. <https://doi.org/10.1371/journal.pone.0128248>
28. Andersen CH, Thomsen PH, Nohr EA, Lemcke S. Maternal body mass index before pregnancy as a risk factor for ADHD and autism in children. *Eur Child Adolesc Psychiatry*. 2018;27(2):139-148. <https://doi.org/10.1007/s00787-017-1027-6>
29. He Y, Chen J, Zhu L-H, Hua L-L, Ke F-F. Maternal smoking during pregnancy and ADHD: results from a systematic review and meta-analysis of prospective cohort studies. *J Atten Disord*. 2020;24(12):1637-1647. <https://doi.org/10.1177/1087054717696766>
30. Rougeaux E, Hope S, Viner RM, Deighton J, Law C, Pearce A. Is mental health competence in childhood associated with health risk behaviors in adolescence? Findings from the UK Millennium Cohort Study. *J Adolesc Health*. 2020;67(5):677-684. <https://doi.org/10.1016/j.jadohealth.2020.04.023>
31. Murray AL, Hall HA, Speyer LG, *et al.* Developmental trajectories of ADHD symptoms in a large population-representative longitudinal study. *Psychol Med*. 2021;1-7. <https://doi.org/10.1017/S0033291721000349>
32. Chang Z, Lichtenstein P, D'Onofrio BM, *et al.* Maternal age at childbirth and risk for ADHD in offspring: a population-based cohort study. *Int J Epidemiol*. 2014;43(6):1815-1824. <https://doi.org/10.1093/ije/dyu204>
33. Torvik FA, Eilertsen EM, McAdams TA, *et al.* Mechanisms linking parental educational attainment with child ADHD, depression, and academic problems: a study of extended families in the Norwegian Mother, Father and Child Cohort Study. *J Child Psychol Psychiatry*. 2020;61(9):1009-1018. <https://doi.org/10.1111/jcpp.13197>
34. Hall HA, Speyer LG, Murray AL, Auyeung B. Prenatal maternal infections and children's neurodevelopment in the UK Millennium Cohort Study: a focus on ASD and ADHD. *J Atten Disord*. 2021;10870547211015422. <https://doi.org/10.1177/10870547211015422>
35. Zeng Y, Tang Y, Tang J, *et al.* Association between the different duration of breastfeeding and attention deficit/hyperactivity disorder in children: a systematic review and meta-analysis. *Nutr Neurosci*. 2020;23(10):811-823. <https://doi.org/10.1080/1028415X.2018.1560905>
36. Bendiksen B, Aase H, Diep LM, Svensson E, Friis S, Zeiner P. The associations between pre-and postnatal maternal symptoms of distress and preschooler's symptoms of ADHD, oppositional defiant disorder, conduct disorder, and anxiety. *J Atten Disord*. 2020;24(7):1057-1069. <https://doi.org/10.1177/1087054715616185>
37. Noonan K, Burns R, Violato M. Family income, maternal psychological distress and child socio-emotional behaviour: longitudinal findings from the UK Millennium Cohort Study. *SSM-Popul Health*. 2018;4:280-290. <https://doi.org/10.1016/j.ssmph.2018.03.002>
38. Sagiv SK, Epstein JN, Bellinger DC, Korrick SA. Pre-and postnatal risk factors for ADHD in a nonclinical pediatric population. *J Atten Disord*. 2013;17(1):47-57. <https://doi.org/10.1177/1087054711427563>
39. Storebø OJ, Rasmussen PD, Simonsen E. Association between insecure attachment and ADHD: environmental mediating factors. *J Atten Disord*. 2016;20(2):187-196. <https://doi.org/10.1177/1087054713501079>
40. Curran EA, Cryan JF, Kenny LC, Dinan TG, Kearney PM, Khashan AS. Obstetrical mode of delivery and childhood behavior and psychological development in a British cohort. *J Autism Dev Disord*. 2016;46(2):603-614. <https://doi.org/10.1007/s10803-015-2616-1>
41. University of London, Institute of Education, Centre for Longitudinal Studies. Millennium Cohort Study: Age 9 months, Sweep 1, 2001. 14th Edition, [data collection]. UK Data Service; 2022. <https://doi.org/10.5255/UKDA-SN-4683-6>
42. Dex S, Joshi H. Millennium Cohort Study, First Survey: A User's Guide to Initial Findings. Centre for Longitudinal Studies, Institute of Education, University of London; 2004.
43. Rutter M, Tizard J, Whitmore K. Health, Education, and Behaviour. Longmans Green; 1970.
44. McGee R, Williams S, Silva PA. An evaluation of the Malaise Inventory. *J Psychosom Res*. 1986;30(2):147-152. [https://doi.org/10.1016/0022-3999\(86\)90044-9](https://doi.org/10.1016/0022-3999(86)90044-9)
45. Condon JT, Corkindale CJ. The assessment of parent-to-infant attachment: development of a self-report questionnaire instrument. *J Reprod Infant Psychol*. 1998;16(1):57-76. [https://doi.org/10.1016/0022-3999\(86\)90044-9](https://doi.org/10.1016/0022-3999(86)90044-9)
46. Su CC, Tsai CY, Tsai TH, Tsai IJ. Incidence and risk of attention-deficit hyperactivity disorder in children with amblyopia: a nationwide cohort study. *Clin Exp Ophthalmol*. 2019;47(2):259-264. <https://doi.org/10.1111/ceo.13465>
47. Hancock KJ, Brennan-Jones CG, Vithiatharan R, *et al.* Mental health problems among 4–17-year-olds with hearing problems: results from a nationally representative study. *Hearing Balance Commun*. 2017;15(3):145-155. <https://doi.org/10.1080/21695717.2017.1325094>
48. DeCarlo DK, Swanson M, McGwin G, Visscher K, Owsley C. ADHD and vision problems in the National Survey of Children's Health. *Optom Vis Sci*. 2016;93(5):459. <https://doi.org/10.1097/OPX.0000000000000823>
49. Bellato A, Perna J, Ganapathy PS, *et al.* Association between ADHD and vision problems. A systematic review and meta-analysis. *Mol Psychiatry*. 2023;28(1):410-422. <https://doi.org/10.1038/s41380-022-01699-0>
50. Franklin MS, Mrazek MD, Anderson CL, *et al.* Tracking distraction: the relationship between mind-wandering, meta-awareness, and ADHD symptomatology. *J Atten Disord*. 2017;21(6):475-486. <https://doi.org/10.1177/1087054714543494>
51. Druker K, Hennessey N, Mazzuchelli T, Beilby J. Elevated attention deficit hyperactivity disorder symptoms in children who stutter. *J Fluency Disord*. 2019;59:80-90. <https://doi.org/10.1016/j.jfludis.2018.11.002>
52. Brikkell I, Ghirardi L, D'Onofrio BM, *et al.* Familial liability to epilepsy and attention-deficit/hyperactivity disorder: a nationwide cohort study. *Biol Psychiatry*. 2018;83(2):173-180. <https://doi.org/10.1016/j.biopsych.2017.08.006>
53. Chou I-C, Chang Y-T, Chin Z-N, *et al.* Correlation between epilepsy and attention deficit hyperactivity disorder: a population-based cohort study. *PLoS One*. 2013;8(3):e57926. <https://doi.org/10.1371/journal.pone.0057926>
54. Wu Y, Li Y, Zhu J, Long J. Shared genetics and causality underlying epilepsy and attention-deficit hyperactivity disorder. *Psychiatry Res*. 2022;316:114794. <https://doi.org/10.1016/j.psychres.2022.114794>
55. Carpena MX, Bonilla C, Matijasevich A, *et al.* Sleep-related traits and attention-deficit/hyperactivity disorder comorbidity: shared genetic risk factors, molecular mechanisms, and causal effects. *World J Biol Psychiatry*. 2021;22(10):778-791. <https://doi.org/10.1080/15622975.2021.1907719>
56. Brainstorm C, Anttila V, Bulik-Sullivan B, *et al.* Analysis of shared heritability in common disorders of the brain. *Science*. 2018;360(6395). <https://doi.org/10.1126/science.aap8757>
57. Allone C, Buono VL, Corallo F, *et al.* Neuroimaging and cognitive functions in temporal lobe epilepsy: a review of the literature. *J Neurol Sci*. 2017;381:7-15. <https://doi.org/10.1016/j.jns.2017.08.007>
58. Friedman NP, Robbins TW. The role of prefrontal cortex in cognitive control and executive function. *Neuropsychopharmacology*. 2022;47(1):72-89. <https://doi.org/10.1038/s41386-021-01132-0>
59. Sun S, Kuja-Halkola R, Chang Z, Cortese S, Almqvist C, Larsson H. Familial liability to asthma and ADHD: a Swedish national register-based study. *JCPP Adv*. 2021;1(4):e12044. <https://doi.org/10.1002/jcv2.12044>
60. Chen M-H, Pan T-L, Hsu J-W, *et al.* Risk of type 2 diabetes in adolescents and young adults with attention-deficit/hyperactivity disorder: a nationwide longitudinal study. *J Clin Psychiatry*. 2018;79(3). <https://doi.org/10.4088/JCP.17m11607>
61. Faraone SV, Larsson H. Genetics of attention deficit hyperactivity disorder. *Mol Psychiatry*. 2019;24(4):562-575. <https://doi.org/10.1038/s41380-018-0070-0>